Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Amarantus Teams With Becton, Dickinson For LymPro Development, Seeking PD-LID Candidate

Amarantus BioSciences (OTCQB:AMBS) is developing a Lymphocyte Proliferation (LymPro) Blood Test for the diagnosis of Alzheimer's Disease. The company acquired the test from privately-held Memory Dx, LLC, in December 2012. The inventors of the test, Dr. Thomas Arendt and Dr. Jens Stieler of the University of Leipzig, Germany, had previously published data and the mechanism of action for LymPro in NeuroReport. We note that LymPro has completed two Phase I clinical studies in over 160 patients, showing 98% sensitivity and 96% specificity for Alzheimer's disease diagnosis.

The next step in the clinical development of LymPro is to establish the analytical performance of the assay in an outsourced GLP laboratory, as well as to conduct small clinical performance studies...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details